相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MicroRNAs in the Diagnosis and Treatment of Cancer
Behzad Mansoori et al.
IMMUNOLOGICAL INVESTIGATIONS (2017)
Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles
Priya Samuel et al.
PROTEOMICS (2017)
The role of miR-26a and miR-30b in HER2+breast cancer trastuzumab resistance and regulation of the CCNE2 gene
Eduardo Tormo et al.
SCIENTIFIC REPORTS (2017)
MiR-146a functions as a small silent player in gastric cancer
Navid Shomali et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy
Marco Tomasetti et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Hiroyuki Ozawa et al.
CLINICAL CANCER RESEARCH (2017)
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Behzad Mansoori et al.
ADVANCED PHARMACEUTICAL BULLETIN (2017)
Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Dennis Shin-Shian Hsu et al.
CLINICAL CANCER RESEARCH (2017)
Laurie acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression
Wen-Hui Weng et al.
ONCOLOGY REPORTS (2016)
MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway
Juan Du et al.
TUMOR BIOLOGY (2016)
Involvement of Numb-mediated HIF-1α inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells
Soraya Sajadimajd et al.
TUMOR BIOLOGY (2016)
Micro RNA 34a and Let-7a Expression in Human Breast Cancers is Associated with Apoptotic Expression Genes
Mansoori Behzad et al.
Asian Pacific Journal of Cancer Prevention (2016)
The role of microRNAs in colorectal cancer
Ali Mohammadi et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells
Behzad Mansoori et al.
CELL CYCLE (2016)
Molecular mechanisms for tumour resistance to chemotherapy
Shu-Ting Pan et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2016)
BACH1, the master regulator gene: A novel candidate target for cancer therapy
Sadaf Davudian et al.
GENE (2016)
Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures
Ida Kjaer et al.
MOLECULAR CANCER THERAPEUTICS (2016)
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1
L. Venturutti et al.
ONCOGENE (2016)
miRNAs: mediators of ErbB family targeted therapy resistance
Barbara Filipa Adem et al.
PHARMACOGENOMICS (2016)
Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression
Fei Xue et al.
ONCOTARGETS AND THERAPY (2016)
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment
Lavinia Raimondi et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer
T. F. Hansen et al.
BRITISH JOURNAL OF CANCER (2015)
Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma
Haixia Cheng et al.
CANCER BIOLOGY & THERAPY (2015)
MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF
Zhenlei Wang et al.
CANCER CELL INTERNATIONAL (2015)
The emerging role of microRNAs in resistance to lung cancer treatments
Lauren MacDonagh et al.
CANCER TREATMENT REVIEWS (2015)
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena et al.
CLINICAL CANCER RESEARCH (2015)
MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1
Paula Mussnich et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Combinational treatment with microRNA-133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR
Jianyu Zhou et al.
MOLECULAR MEDICINE REPORTS (2015)
miRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation
Tao Ma et al.
ONCOLOGY REPORTS (2015)
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance
A. De Cola et al.
CELL DEATH & DISEASE (2015)
Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Friederike Braig et al.
ONCOTARGET (2015)
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer
Gloria Bertoli et al.
THERANOSTICS (2015)
MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation
Toshinaga Suto et al.
CARCINOGENESIS (2015)
The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway
Kojiro Eto et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
S. E. Moody et al.
ONCOGENE (2015)
The MicroRNA-21/PTEN Pathway Regulates the Sensitivity of HER2-Positive Gastric Cancer Cells to Trastuzumab
Kojiro Eto et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN
Xingming Ye et al.
BMB REPORTS (2014)
Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
Xing-Ming Ye et al.
BMC CANCER (2014)
MiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer
Guang-jun Zhang et al.
BMC CANCER (2014)
Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma
Kristina Y. Aguilera et al.
CANCER RESEARCH (2014)
MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors
Paolo Luraghi et al.
CANCER RESEARCH (2014)
AXL Mediates Resistance to Cetuximab Therapy
Toni M. Brand et al.
CANCER RESEARCH (2014)
PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer-Results from NCIC CTG/AGITG CO.17
Christos S. Karapetis et al.
CLINICAL CANCER RESEARCH (2014)
MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
Wen-Dong Bai et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy
Josep Lluis Parra-Palau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
miR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3
Lei Liu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Identification of genomic alterations in oesophageal squamous cell cancer
Yongmei Song et al.
NATURE (2014)
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
D. Raina et al.
ONCOGENE (2014)
The role of microRNAs in human breast cancer progression
WenCheng Zhang et al.
TUMOR BIOLOGY (2014)
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Nicolo Rigamonti et al.
CELL REPORTS (2014)
The role of microRNA in resistance to breast cancer therapy
Neil M. Robertson et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2014)
Downregulation of Ca2+-Activated Cl- Channel TMEM16A by the Inhibition of Histone Deacetylase in TMEM16A-Expressing Cancer Cells
Sayo Matsuba et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
AngiomiR-126 expression and secretion from circulating CD34+ and CD14+ PBMCs: role for proangiogenic effects and alterations in type 2 diabetics
Pavani Mocharla et al.
BLOOD (2013)
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels
Stefano Kim et al.
BMC CANCER (2013)
Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors
Anindita Chakrabarty et al.
CANCER RESEARCH (2013)
Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models
Roberta Rosa et al.
CLINICAL CANCER RESEARCH (2013)
Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Arman Jahangiri et al.
CLINICAL CANCER RESEARCH (2013)
Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET?
Joseph H. McCarty
CLINICAL CANCER RESEARCH (2013)
Angiopoietin signaling in the vasculature
Lauri Eklund et al.
EXPERIMENTAL CELL RESEARCH (2013)
MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab
Aubrey G. Wagenseller et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells
Gang Chen et al.
PLOS ONE (2013)
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Lisa M. Coussens et al.
SCIENCE (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Alexandra Canonici et al.
ONCOTARGET (2013)
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
Anna Tamburrino et al.
FRONTIERS IN PHARMACOLOGY (2013)
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Eun-Jung Jung et al.
CANCER (2012)
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Kan V. Lu et al.
CANCER CELL (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression
C. Oneyama et al.
ONCOGENE (2012)
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Toni M. Brand et al.
CANCER BIOLOGY & THERAPY (2011)
miR-99 Family of MicroRNAs Suppresses the Expression of Prostate-Specific Antigen and Prostate Cancer Cell Proliferation
Dandan Sun et al.
CANCER RESEARCH (2011)
The Evolving War on Cancer
Daniel A. Haber et al.
CELL (2011)
HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
David Liska et al.
CLINICAL CANCER RESEARCH (2011)
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Chang Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
Hiroyuki Inuzuka et al.
NATURE (2011)
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Ingrid E. Wertz et al.
NATURE (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
MicroRNA miR-125b induces senescence in human melanoma cells
Martin Glud et al.
MELANOMA RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Maurizio Scaltriti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1
William C. S. Cho et al.
RNA BIOLOGY (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
Autophagy is a therapeutic target in anticancer drug resistance
Suning Chen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2010)
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
V. Goede et al.
BRITISH JOURNAL OF CANCER (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment
Marco Ragusa et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma
Hiromitsu Hatakeyama et al.
PLOS ONE (2010)
Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Olivier Cuvillier et al.
Current Molecular Pharmacology (2010)
Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines
Long Gu et al.
CLINICAL CANCER RESEARCH (2009)
Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma
Iris Helfrich et al.
CLINICAL CANCER RESEARCH (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Tumor suppressors and cell metabolism: a recipe for cancer growth
Russell G. Jones et al.
GENES & DEVELOPMENT (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
Salvatore Siena et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
Kim Pedersen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
CANCER The nuances of therapy
Lee M. Ellis et al.
NATURE (2009)
Nuclear EGFR contributes to acquired resistance to cetuximab
C. Li et al.
ONCOGENE (2009)
Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
Alejandro Vazquez-Martin et al.
PLOS ONE (2009)
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi et al.
PLOS ONE (2009)
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
David L. Shattuck et al.
CANCER RESEARCH (2008)
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases
Xi Chen et al.
CELL RESEARCH (2008)
The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis
Shusheng Wang et al.
DEVELOPMENTAL CELL (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Detection of microRNA Expression in Human Peripheral Blood Microvesicles
Melissa Piper Hunter et al.
PLOS ONE (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression
Hong-Jun Liao et al.
MOLECULAR BIOLOGY OF THE CELL (2007)
Modulation of mRNA stability as a novel therapeutic approach
Wolfgang Eberhardt et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway
Xiao-Feng Le et al.
CELL CYCLE (2006)
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis
Kurt Degenhardt et al.
CANCER CELL (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
An economic evaluation of Herceptin® in adjuvant setting:: The Breast Cancer International Research Group 006 trial
M Neyt et al.
ANNALS OF ONCOLOGY (2006)
Comparing antibody and small-molecule therapies for cancer
Kohzoh Imai et al.
NATURE REVIEWS CANCER (2006)
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2005)
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells
SJ Isakoff et al.
CANCER RESEARCH (2005)
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients
CG Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody
Y Wang et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Novel DNA-binding properties of the RNA-binding protein TIAR
EA Suswam et al.
NUCLEIC ACIDS RESEARCH (2005)
A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery
TY Lee et al.
CANCER RESEARCH (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Update on HER-2 as a target for cancer therapy - Intracellular signaling pathways of ErbB2/HER-2 and family members
MA Olayioye
BREAST CANCER RESEARCH (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report
C Vogel et al.
EUROPEAN JOURNAL OF CANCER (2001)
分享论文
